ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DERM vs CUE // EV/EBITDA & P/E VALUATION

Journey Medical Corporation (NASDAQ) VS. Cue Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: DERM 5 — CUE 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. CUE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DERM CUE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 65.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -19.50% -35.00% +15.50 DERM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -8.15% -14.03% +5.88 DERM /fcf-yield <GO>
Operating Margin -13.30% -60.00% +46.70 DERM /operating-margins <GO>
Net Profit Margin -18.70% -60.00% +41.30 DERM /net-margins <GO>
Revenue Growth (YoY) 11.10% 180.00% -168.90 CUE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.74 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 DERM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 46.7 -6.24 CUE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $152.7M $155.8M -$3.1M CUE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DERM REV CUE REV DERM GROSS % CUE GROSS % DERM FCF CUE FCF
FY 2025 $61.2M $27.5M 65.8% — -$12.4M -$21.9M
FY 2024 $55.1M $9.3M 62.1% — -$9.1M -$36.4M
FY 2023 $59.7M $5.5M — — $5.2M -$40.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
CUE // BETA —